Ascentage Pharma Group International

NASDAQ:AAPG

Biotechnology

Healthcare
$13.01 +1.78%

+$0.31 today

Market cap
$1.21B
Beta
0.65
P/E (TTM)
-8.9
EPS (TTM)
-$13.29
52W Low $16.92High $48.45

Volume 0.00M

Average 0.01M

AAPG Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Ascentage Pharma Group InternationalNASDAQ: AAPG

Gross Profit · Q4 FY2025 · quarter ended Dec 2025

Gross profit grows 85.8% year over year

Q4 FY2025 gross profit of CN¥265.45M rose 85.8% year over year. Over 3 fiscal years it compounded at +31.5% a year.

Context

  • Gross profit amounted to 76.4% of revenue in FY2025, down 20.6 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
CN¥265.45M— QoQ
Last fiscal yearDec 2025
CN¥426.75M-55.2% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+85.8%——
1 year-55.2%——
3-year CAGR+31.5%——
5-year CAGR——
10-year CAGR——

Gross Profit history

CNY · from the income statement

Latest · FY2025
426.75M CNY
Year-over-year change
-55.2%
4-year CAGR
+104.1%

Gross Profit vs competitors

How AAPG compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -55.2% is the 7th highest of 9, against a peer median of +34.0%.
  • Gross profit amounts to 76.4% of revenue for AAPG, versus a peer median of 86.5%.
AAPG Competitors
Gross Profit for AAPG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$607.18M USD+545.5%—86.5%
AAPGAscentage Pharma Group InternationalFY2025CN¥426.75M CNY-55.2%+31.5%76.4%
ZLABZai Lab LimitedLTM Jun 2026$253.9M USD-4.9%+24.0%56.5%
NUVBNuvation Bio Inc.LTM Jun 2026$159.6M USD+3936.4%—93.9%
VSTMVerastem, Inc.LTM Mar 2026$41.53M USD+315.3%+114.5%83.7%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$33.06M USD-2.5%-3.5%94.8%
ANLAdlai Nortye Ltd.LTM Jun 2024$6.49M USD——100.0%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
IMRXImmuneering CorporationLTM Mar 2026-$793.21K USD-354.2%——
TNGXTango Therapeutics, Inc.LTM Sep 2026-$942K USD-101.4%+34.2%—
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-$19.69M USD+70.5%+63.7%8.7%
Peer median (excluding AAPG) —+34.0%+34.2%86.5%

Competitors are the stored peer set for AAPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.91M209.71M221.98M980.65M558.48M
Cost of Revenue3.33M22M30.54M29.09M131.73M
Gross Profit24.58M187.71M191.44M951.57M426.75M
Gross Margin88.1%89.5%86.2%97.0%76.4%
Research & Development766.49M743.1M706.97M947.25M1.08B
Selling, General & Admin191.26M328.02M376.46M383.12M522.67M
Operating Expenses957.75M1.04B1.06B1.32B1.61B
Depreciation & Amortization17.18M47.42M93.2M93.17M84.12M
EBITDA(798.34M)(786.97M)(743.61M)(237.63M)(1.1B)
EBITDA Margin-2860.4%-375.3%-335.0%-24.2%-196.1%
Operating Income(869.84M)(849.81M)(872.64M)(369.73M)(1.18B)
Operating Margin-3116.6%-405.2%-393.1%-37.7%-211.1%
Interest Income7.11M9.73M32.41M37.84M79.89M
Interest Expense16.73M52.79M96.06M64.46M52.6M
Other Income / Expenses37.59M(37.36M)(60.23M)(25.53M)(23.21M)
Income Before Tax(832.25M)(887.17M)(932.86M)(395.26M)(1.2B)
Pre-Tax Margin-2981.9%-423.0%-420.2%-40.3%-215.3%
Income Tax Expense(49.83M)(4.25M)(7.15M)10.43M6.75M
Net Income(782.42M)(882.92M)(925.64M)(405.43M)(1.21B)
Net Margin-2803.4%-421.0%-417.0%-41.3%-216.5%
EPS (Basic)(49.12)(53.60)(52.48)(5.36)(13.56)
EPS (Diluted)(49.12)(53.60)(52.48)(5.36)(13.56)
Weighted Avg Shares15.91M16.48M17.64M75.52M89.03M
Weighted Avg Shares (Diluted)15.91M16.48M17.64M75.52M89.03M

Ascentage Pharma Group International

NASDAQ:AAPG

Intrinsic Alpha fair value

Locked

Current Price

$13.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.